A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Clinical trial NCT05856760 · COMPLETED
Trial details
- NCT number
- NCT05856760
- Sponsor
- Travere Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-05-19
- Primary completion
- 2024-10-14
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.